

## Cipla scored highest among pharma companies in CRISIL's Sustainability Rating 2022

- Among top 5 companies in the manufacturing sector

**Mumbai, India; May 25, 2022:** Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") announced today that it has been rated 'STRONG' in the Sustainability Yearbook 2022 released by CRISIL, a leading rating agency in India. Based on the fiscal 2021 data, CRISIL analysed 586 companies across 53 sectors for over 350+ datapoints on Environment, Social and Governance (ESG) components for evaluation. Cipla is amongst the top 5 companies in the manufacturing sector and has the highest ESG score amongst peers in the pharmaceutical sector.

Commenting on the rating, **Ms. Geena Malhotra, Global Chief Technology Officer who is spearheading Cipla's ESG efforts** said, "We are humbled and honored to receive this rank in CRISIL's Sustainability report. It is a true testament to our relentless efforts and commitment towards sustainability which is embedded in our DNA at Cipla. Guided by our ethos of Caring for Life, we will continue to build sustainable solutions across markets for a healthier planet and society. It gives us great joy to be recognized for our efforts and we will continue to raise the bar going ahead."

In 2021, Cipla was recognized among the top 30 companies under the Indian Corporate Governance Scorecard 2021 and ranked as one of the most sustainable companies in the Dow Jones Sustainability Emerging Markets Index. Cipla also won the prestigious Frost & Sullivan and TERI's Sustainability 4.0 Award 2021 as "Challenger in Mega Large Business Pharma Sector".

The company's Global ESG positioning **C.A.R.E: Championing Climate Positivity | Accelerating Community Well-being | Raising the Bar on Governance | Enhancing Access & Affordability** is aimed at developing a holistic sustainability road map for the future. By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.

### **About Cipla:**

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Mar'22), 3rd largest in the pharma private market in South Africa (IQVIA MAT Mar'22), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring forLife' and deep-rooted community links wherever it is

### **Cipla Ltd.**

**Regd. Office** -Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India.

**P** +91 22 24826000 **F** +91 22 24826120 **W** www.cipla.com **E-Mail** contactus@cipla.com **Corporate Identity Number** L24239MH1935PLC002380

present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit [www.cipla.com](http://www.cipla.com), or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

**For Further Information, please contact:**

**CIPLA:**

**Corporate Communications**

Heena Kanal

Email: [CorpComm@cipla.com](mailto:CorpComm@cipla.com)

**Investor Relations**

Naveen Bansal

E-Mail: [Investor.Relations@cipla.com](mailto:Investor.Relations@cipla.com)